Aurinia Pharmaceuticals (LTS:0UJF) Research & Development: C$47.1 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0UJF Aurinia Pharmaceuticals Inc LTS:0UJF
81 GF Score
Price C$15.41
GF Value C$13.55
! 4 Warning Signs
View Full Analysis

What is Aurinia Pharmaceuticals Research & Development?

Aurinia Pharmaceuticals LTS:0UJF 81 Research & Development is C$47.1 Mil as of Mar. 2026. GuruFocus rates LTS:0UJF with a GF Score™ of 81/100 and a GF Value™ of C$13.55. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Aurinia Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was C$10.2 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was C$47.1 Mil.

Aurinia Pharmaceuticals  (LTS:0UJF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Aurinia Pharmaceuticals Research & Development Related Terms

Aurinia Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Aurinia Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals Research & Development Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.46 61.12 66.60 29.61 44.84

Aurinia Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.25 10.16 11.67 15.03 10.25
LTS:0UJF
81GF Score
Aurinia Pharmaceuticals Inc LTS:0UJF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurinia Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$47.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of C$47.1 Mil mean?
Aurinia Pharmaceuticals (LTS:0UJF) has a Research & Development of C$47.1 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Aurinia Pharmaceuticals and its competitors.
Is Aurinia Pharmaceuticals' Research & Development too high?
Aurinia Pharmaceuticals' current Research & Development is C$47.1 Mil. Overall, Aurinia Pharmaceuticals has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' Research & Development compare to KOD and ABCL?
Aurinia Pharmaceuticals' Research & Development of C$47.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Aurinia Pharmaceuticals and its competitors. Aurinia Pharmaceuticals's current Research & Development is C$47.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Aurinia Pharmaceuticals (LTS:0UJF) has a current Research & Development of C$47.1 Mil. The stock's GF Value™ is C$13.55, compared to a current price of C$15.41 — trading 13.7% above its estimated fair value. The current Research & Development is C$47.1 Mil. Aurinia Pharmaceuticals' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Aurinia Pharmaceuticals (LTS:0UJF), the current Research & Development is C$47.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurinia Pharmaceuticals (LTS:0UJF) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of C$15.41 is trading 13.7% above its estimated GF Value™ of C$13.55.

Key valuation signals for LTS:0UJF:

  • Research & Development: C$47.1 Mil
  • GF Value™: C$13.55 vs. price of C$15.41 (13.7% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the LTS:0UJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aurinia Pharmaceuticals Business Description

Other Exchanges AUPH:USAIKAP:Germany
Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
81GF Score

Get the complete analysis for LTS:0UJF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$15.41
Price
C$13.55
GF Value